moxifloxacin has been researched along with irinotecan in 7 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (irinotecan) | Trials (irinotecan) | Recent Studies (post-2010) (irinotecan) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 8,002 | 1,885 | 3,752 |
| Protein | Taxonomy | moxifloxacin (IC50) | irinotecan (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 2.7 | |
| Interstitial collagenase | Homo sapiens (human) | 6.06 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.556 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.171 | |
| Acetylcholinesterase | Homo sapiens (human) | 1.827 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 7.9 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 4.7667 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Askenasy, N; Fabian, I; Halperin, D; Reuveni, D; Shalit, I; Tsarfaty, G | 1 |
1 review(s) available for moxifloxacin and irinotecan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for moxifloxacin and irinotecan
| Article | Year |
|---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors.
Topics: Angiogenesis Inhibitors; Animals; Anti-Infective Agents; Antineoplastic Agents; Aza Compounds; Camptothecin; Cell Proliferation; Drug Synergism; Female; Fluoroquinolones; Humans; Interleukin-8; Irinotecan; Mice; Mice, SCID; Moxifloxacin; Neoplasms, Experimental; Platelet Endothelial Cell Adhesion Molecule-1; Quinolines; Ultrasonography, Doppler; Xenograft Model Antitumor Assays | 2010 |